Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

SANUWAVE Health (SNWV) Shares Outstanding (Diluted Average) (2023 - 2025)

SANUWAVE Health (SNWV) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $9.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 103.52% to $9.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Dec 2025, up 103.52% year-over-year, with the annual reading at $9.1 million for FY2025, 103.52% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $9.1 million at SANUWAVE Health, down from $9.1 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $893.0 million in Q3 2023, with the low at $3.2 million in Q3 2024.
  • Average Shares Outstanding (Diluted Average) over 3 years is $189.2 million, with a median of $9.1 million recorded in 2025.
  • The sharpest move saw Shares Outstanding (Diluted Average) tumbled 99.64% in 2024, then soared 186.99% in 2025.
  • Over 3 years, Shares Outstanding (Diluted Average) stood at $893.0 million in 2023, then plummeted by 99.5% to $4.5 million in 2024, then surged by 103.52% to $9.1 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $9.1 million, $9.1 million, and $9.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.